Physician profile
Wayne Cheng
NPI 1881783074
$10,234.32
in general payments reported to CMS, 2019-2025
32 companies · $3,400 in 2025
The $3,400 reported for 2025 was more than what 89% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,233 · 2020: $734 · 2021: $1,314 · 2022: $531 · 2023: $566 · 2024: $2,456 · 2025: $3,400.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,997 · Travel and Lodging: $2,426.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,996.81 |
| Travel and Lodging | $2,425.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $2,638.68 | 2019-2025 | Triclip |
| Medtronic, INC. | $1,763.70 | 2021-2025 | Kyphon Express II Kyphopak Tray, Intellis Adaptivestim, Osteocool Rf Ablation System |
| Edwards Lifesciences Corporation | $1,505.22 | 2025 | Evoque |
| Amgen INC. | $538.76 | 2019-2025 | Repatha, Repatha |
| Pfizer INC. | $492.18 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $464.29 | 2019-2025 | Jardiance |
| Medtronic Vascular, INC. | $373.94 | 2019-2020 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $345.89 | 2019-2025 | Lifevest |
| Novartis Pharmaceuticals Corporation | $258.36 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $212.71 | 2019-2025 | Camzyos, Eliquis |
| Janssen Pharmaceuticals, INC | $211.77 | 2019-2024 | Xarelto |
| Stryker Corporation | $170.36 | 2025 | N/A, Scopis Ent |
| Astrazeneca Pharmaceuticals LP | $166.40 | 2019-2025 | Farxiga, Lokelma |
| Bayer Healthcare Pharmaceuticals INC. | $141.28 | 2025 | |
| Cvrx, INC. | $130.28 | 2021 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $129.54 | 2019-2021 | |
| Novo Nordisk INC | $113.24 | 2024-2025 | Wegovy, Ozempic |
| Scpharmaceuticals INC. | $105.76 | 2024-2025 | |
| Esperion Therapeutics, INC. | $102.94 | 2021-2025 | Nexletol, Nexlizet |
| Nuwellis, INC. | $60.42 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $55.06 | 2019-2022 | |
| Kowa Pharmaceuticals America, INC. | $40.91 | 2019-2023 | Livalo |
| Alnylam Pharmaceuticals INC. | $35.89 | 2025 | Onpattro |
| Actelion Pharmaceuticals US, INC. | $25.40 | 2025 | Uptravi |
| Kiniksa Pharmaceuticals International, Plc | $23.54 | 2024 | Arcalyst |
| Astellas Pharma US INC | $23.40 | 2020 | |
| Merck Sharp & Dohme LLC | $21.99 | 2023 | Verquvo |
| Philips North America LLC | $20.06 | 2023 | |
| Kiniksa Pharmaceuticals, LTD. | $18.84 | 2023 | Arcalyst |
| Penumbra, INC. | $14.84 | 2022 | |
| Boston Scientific Corporation | $14.34 | 2019 | |
| Chiesi USA, INC. | $14.33 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Wayne Cheng listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.